Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

Схожие документы

• Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia
  по: Hayette, Sandrine, et al.
  Опубликовано: (2009)
• Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
  по: Gabriel Etienne, et al.
  Опубликовано: (2019-09-01)
• Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
  по: Etienne, Gabriel, et al.
  Опубликовано: (2019)
• α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients
  по: Etienne, Gabriel, et al.
  Опубликовано: (2011)
• The pharmacogenetics of imatinib
  по: Dulucq, Stéphanie, et al.
  Опубликовано: (2010)